Lucid Diagnostics (LUCD) IPO: 7 Things to Know
Get Alerts LUCD Hot Sheet
Join SI Premium – FREE
Lucid Diagnostics (NASDAQ: LUCD), which produces diagnostic tests for esophageal precancer and cancer, is scheduled to go public next week. Here are 7 key things to know about the upcoming LUCD IPO.
1. Lucid Diagnostics IPO Date - Lucid Diagnostics is due to go public on October 14, 2021. Lucid Diagnostics will start trading under the ticker symbol “LUCD” on the Nasdaq stock exchange. Generally, shares that make their public stock market debuts start trading between 10 AM - 2 PM ET.
2. Lucid Diagnostics IPO Pricing - LUCD is expected to price its shares between $14.00 and $16.00.
3. Shares Offered - Lucid Diagnostics is looking to sell 5,000,000 shares of its common stock. The S-1 filing shows the number of outstanding shares after IPO offering would be 36,992,077 shares.
4. LUCD IPO Valuation - Lucid Diagnostics is seeking a valuation of between $517.9 million and $591.8 million.
5. LUCD IPO Raised Proceeds: At the midpoint of the pricing range, Lucid Diagnostics is looking to raise $75 million. The company plans to use the raised proceeds to expand sales infrastructure, optimize the pilot launch of new products, complete ongoing clinical trials, and expand manufacturing capacities.
6. LUCD IPO Underwriters - Cantor and Canaccord Genuity are joint bookrunners. BTIG and Needham & Company are co-lead managers.
7. LUCD Financials - The company reported a loss of $9.8 million for the first half of the year. LUCD said in the filing it expects to “continue to incur operating losses for the foreseeable future.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U-BX Technology (UBXG) IPO Opens At $5, Priced at $5
- Reitar Logtech Holdings (RITR) Announces 2.5M Share IPO at $4-$5/sh
- Praxis Precision Medicines (PRAX) Announces Proposed Share Offering
Create E-mail Alert Related Categories
IPOs, Insiders' BlogRelated Entities
Needham & Company, S1, Canaccord Genuity, IPO, BTIGSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!